GILD · Earnings call · 2026Q3T · Full report
Income Tax Rate Changes
GILEAD SCIENCES, INC. · 2026-10-29 · Importance 28 · Surprise 42 · In source text
The third-quarter 2026 non-GAAP effective tax rate was 19%, in line with Gilead’s full-year expectation of approximately 20% excluding acquired IPR&D. The company’s reported full-year 2026 effective tax-rate guidance is stated as between 220% and 165%, reflecting nondeductible acquired IPR&D from the Arcellx, Tubulis and Ouro Medicines transactions and the expected PepStar Therapeutics transaction. Excluding those transactions, the company expects a 20% effective tax rate, unchanged from its February guidance.
Key facts
- Gilead's full-year 2026 effective tax rate guidance was 220%-165%, including nondeductible acquired IPR&D; excluding the transactions, the expected rate was 20%.
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| net_income | negative | committed | — | Gilead's full-year 2026 effective tax rate guidance was 220%-165%, including nondeductible acquired IPR&D; excluding the transactions, the… |